Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.
Kåre Inge BirkelandJohan BodegardAmitava BanerjeeDae-Jung KimAnna NorhammarJan W ErikssonMarcus ThuressonSuguru OkamiKyoung Hwa HaNils KossackJil Billy MamzaRuiqi ZhangToshitaka YajimaIssei KomuroTakashi KadowakiPublished in: Diabetes, obesity & metabolism (2020)
In this multinational observational study, SGLT2i was associated with a lower risk of HF and CKD versus DPP4i in patients with type 2 diabetes otherwise free from both cardiovascular and renal disease.